Abstract
Background: Glial cell-derived tumours of the central nervous system make up the largest group of brain tumours. Most are high-grade gliomas (HGG) and are universally fatal despite multimodal therapy. With a suspected HGG, surgery is undertaken for tumour de-bulking and to make a definitive diagnosis. While the tumour genetics provides some insight on prognosis, it rarely changes decision-making, nor does it predict recurrence. In managing patients with HGG, predicting recurrence, or differentiating between pseudoprogression (radiation necrosis) and true tumour progression would be invaluable in improving overall prognosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
